Nuvation Bio Inc. (NUVB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 8 | 63 | 170 | 197 |
| Operating profit | $m | -213 | -138 | ||||||
| Net profit | $m | -42 | -87 | -104 | -76 | -568 | -205 | -150 | -132 |
| EPS reported | $ | -0.60 | -0.44 | ||||||
| Operating cashflow per share | $ | -0.51 | -0.24 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.51 | -0.24 | ||||||
| Free cash flow | $m | -174 | -83 | ||||||
| Net debt | $m | -519 | -412 | ||||||
| Book value equity | $m | 306 | 254 | ||||||
| Book value per share | $ | 0.90 | 0.73 | ||||||
| Number of shares | m | 341.54 | 348.77 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 10.01 | 12.05 | ||||||
| P/S LTM | x | 48.65 | 18.01 | ||||||
| P/FCF LTM | x | -17.61 | -36.99 | ||||||
| EV/EBITDA LTM | x | -15.36 | -22.88 | ||||||
| EV/Sales LTM | x | 46.20 | 12.67 | ||||||
| Earnings Yield LTM | % | -6.69% | -6.91% | ||||||
| FCF Yield | % | -5.68% | -2.70% | ||||||
| Quality | |||||||||
| ROE | % | -66.93% | -49.73% | ||||||
| ROIC | % | -40.96% | -20.68% | ||||||
| Operating margin | % | -3.39% | -81.00% | ||||||
| Gross margin | % | +86.58% | +93.94% | ||||||
| FCF/Sales | % | -276.27% | -48.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +698.96% | +2058.0% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -17.13 | -0.33 | ||||||
| Net Debt/EBITDA | x | 0.81 | 0.05 | ||||||
| EBIT/Net interest | x | -15.57 | -5.16 | ||||||
| Net debt/market cap | % | +0.33% | +11.60% | ||||||
| Net debt/Equity | x | -1.70 | -1.62 | ||||||
| Gross debt/equity | x | 0.03 | 0.99 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free